This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Colorectal cancer	UDP <i>glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1); ATP-binding cassette sub-family C (CFTR/MRP) member 1 (ABCC1)</i>	A study in patient samples identified a set of markers that could be useful for predicting risk and severity of irinotecan-induced neutropenia in colorectal cancer patients. In samples from a cohort of 85 advanced cancer patients, genetic variations in <i>UGT1A1</i> and <i>ABCC1</i> , together with gender and race, accounted for almost 50% of the variation in absolute neutrophil counts ($p < 0.0001$). Next steps include validating the markers in independent patient cohorts. Pfizer Inc. markets the topoisomerase I inhibitor Camptosar irinotecan to treat colon cancer.	Work patented; additional patents pending; available for licensing from The University of Chicago Technology Transfer Office Contact: Matthew R. Martin, The University of Chicago, Chicago, Ill. phone: 773-702-1692 e-mail: mmartin@tech.uchicago.edu	Innocenti, F. <i>et al. J. Clin. Oncol.</i> ; published online April 6, 2009; doi:10.1200/JCO.2008.20.6300 Contact: Federico Innocenti, The University of Chicago, Chicago, Ill. e-mail: finnocen@medicine.bsd.uchicago.edu
<i>SciBX</i> 2(16); doi:10.1038/scibx.2009.652 Published online April 23, 2009				